CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
- Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA technology to develop novel treatment approaches Company expects to deliver two or more clinical candidates by the end of 2025 and plans to initiate at least two new Phase 1 studies by the end of 2026 Cash runway extended into 2028 through combination of new licensing agreement with GSK, reduced operating expenses and enhanced financial discipline TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need.
- 07/03/2024
|
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
- GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced LONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA development activities.
- 07/03/2024
|
GSK buys full rights to make COVID, influenza vaccines from CureVac
- GSK has bought from CureVac 5CV.DE, CVAC.O the full rights to develop and manufacture vaccine candidates for influenza and COVID-19 that use messenger RNA (mRNA) technology for up to 1.05 billion euros ($1.13 billion), it said on Wednesday.
- 07/03/2024
|
CureVac Announces Voting Results of General Meeting
- TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 24, 2024 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's annual general meeting.
- 06/24/2024
|
3 Stocks to Purge ASAP Before They're Pulled off Life Support
- There are several stocks to sell now that are clinging to life support. These companies have been diluting their shares and burning cash at an alarming rate, making a successful comeback an increasingly unlikely prospect.
- 05/10/2024
|
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
- Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs Together with GSK, ended Pandemic Preparedness Agreement (PPA) with Federal Republic of Germany, after consultation with the German Federal Ministry of Health Cash and cash equivalents position of €402.5 million as of December 31, 2023; cash runway extended into Q4 2025 with organizational redesign and despite PPA wind-down Strategic collaboration signed with world-leading oncology center MD Anderson, creating unique expertise to jointly discover and develop novel cancer vaccines Appointment of Thaminda Ramanayake as Chief Business Officer, bringing more than 15 years of biopharma company development and deal-making experience Promising COVID-19 and seasonal flu Phase 2 data confirms proprietary mRNA platform elicits strong overall antibody titers at well-tolerated dose levels New Phase 1/2 study in avian flu started in collaboration with GSK addressing potential future pandemic threat Successful safety review of data from glioblastoma Phase 1 Part A with multiepitope cancer vaccine candidate, CVGBM, enables progressing to Part B with expected start mid-2024 CureVac to host conference call and webcast today at 9 a.m. ET / 3 p.m.
- 04/24/2024
|
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
- Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone Avian influenza is latest program progressing to clinical trials under broad infectious disease collaboration agreement with GSK TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 24, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the start of the Phase 1 part of a combined Phase 1/2 study of an investigational influenza A (H5N1) pre-pandemic vaccine candidate developed in collaboration with GSK.
- 04/24/2024
|
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
- Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 24, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Thaminda Ramanayake has been appointed to the role of Chief Business Officer, effective June 1, 2024.
- 04/24/2024
|
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
- TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourth quarter and full-year 2023 on Wednesday, April 24, 2024.
- 04/18/2024
|
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
- Agreement creates strong synergies between CureVac's unique end-to-end mRNA capabilities and MD Anderson's translational and clinical research expertise Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need MD Anderson responsible for leading initial Phase 1/2 studies; CureVac retains worldwide exclusive rights to late-stage development, commercialization, or partnering of cancer vaccine candidates TÜBINGEN, GERMANY and HOUSTON, TX / ACCESSWIRE / April 16, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
- 04/16/2024
|
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
- Potentially differentiated, multivalent candidate encodes antigens matched to all four WHO-recommended flu strains For influenza A strains, geometric mean titers numerically exceeded those elicited by the licensed comparator vaccines consistently across all tested dose levels and age groups For influeSeasonal flu vaccine candidate boosted antibody titers at all dose levels and for all encoded seasonal influenza strains across younger and older adults nza B strains, geometric mean titers were lower than those elicited by the licensed comparator vaccines, in line with expectations and other initial mRNA-based clinical flu development programs Further optimizations to enhance immune responses against influenza B strains will be tested in additional Phase 2 study Candidate showed acceptable safety profile, confirming previous findings that the proprietary platform elicits strong overall antibody titers at well-tolerated dose levels TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced interim data from an ongoing Phase 2 part of the combined Phase 1/2 study of its seasonal influenza vaccine candidate, conducted in collaboration with GSK.
- 04/04/2024
|
Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)
- CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
- 01/26/2024
|
Down -15.09% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)
- The heavy selling pressure might have exhausted for CureVac N.V. (CVAC) as it is technically in oversold territory now.
- 01/25/2024
|
CureVac stock gains as COVID vaccine candidates show promise
- CureVac N.V. shares CVAC, +1.20% gained 3% premarket on Friday as the company released new data from a trial of its mRNA COVID-19 vaccine candidates, which it is developing in collaboration with GSK PLC GSK, +0.39%.
- 01/05/2024
|
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
- Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profile Monovalent mRNA vaccine candidate, CV0601, encoding Omicron BA.4-5 variant and bivalent candidate, CV0701, encoding Omicron BA.4-5 variant as well as the original SARS-CoV-2 virus, successfully boosted antibody titers and were generally well tolerated across all tested dose levels TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 5, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced positive interim data from the ongoing Phase 2 study assessing monovalent and bivalent modified vaccine candidates against COVID-19.
- 01/05/2024
|
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
- Validity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by BioNTech SE Decision does not affect ongoing litigation in Germany regarding seven other intellectual property rights, covering strong foundational as well as COVID-19-specific mRNA innovation CureVac to appeal before the German Federal Court of Justice, while remaining confident in the strength of its broad intellectual property portfolio TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / December 19, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the nullity action filed by BioNTech SE against the German part of CureVac patent EP 1 857 122 B1 was granted by the German Federal Patent Court.
- 12/19/2023
|
Can CureVac N.V. (CVAC) Climb 191.74% to Reach the Level Wall Street Analysts Expect?
- The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 191.7% upside in the stock.
- 11/21/2023
|
CureVac N.V. (CVAC) Q3 2023 Earnings Call Transcript
- CureVac N.V. (NASDAQ:CVAC ) Q3 2023 Earnings Conference Call November 14, 2023 9:00 AM ET Company Participants Sarah Fakih - VP, Corporate Communications and IR Alexander Zehnder - CEO Pierre Kemula - CFO Myriam Mendila - CDO Marcus Dalton - Head, Intellectual Property Conference Call Participants Evan Wang - Guggenheim Ellie Merle - UBS Eun Yang - Jefferies Charlie Yang - Bank of America Operator Greetings and welcome to the CureVac Financial Results for Third Quarter and First Nine Months of 2023 Business Update.
- 11/14/2023
|
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
- CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024 First participant dosed in seasonal flu Phase 2 study with potentially differentiated multivalent candidate; €15 million milestone payment by GSK triggered Phase 1 study in glioblastoma well on track with opening of third dose level for CVGBM, CureVac's multiepitope cancer vaccine candidate Preclinical data with multiepitope construct in oncology shows strong T cells responses and significantly extended survival in checkpoint-inhibitor resistant melanoma model Infringement ruling on four intellectual property rights postponed by Regional Court Düsseldorf pending separate validity ruling in German patent litigation against BioNTech; postponement suggests court will find all four rights to be infringed The RNA Printer® achieved first milestone, obtaining manufacturing license for GMP-grade mRNA manufacturing in cancer vaccine development Chief Business and Commercial Officer to leave CureVac at the end of his term, effective November 30, 2023 Cash and cash equivalents position of €464.1 million as of September 30, 2023 CureVac to host conference call and webcast today at 9 a.m. ET / 3 p.m.
- 11/14/2023
|
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
- COVID-19 Phase 2 clinical trial fully enrolled Study compares mono- and bivalent vaccine candidates against licensed comparator COVID-19 vaccine First participant dosed in seasonal flu Phase 2 part of combined Phase 1/2 study Study compares a potentially differentiated, multivalent vaccine candidate with broad antigen coverage against licensed comparator vaccine TÜBINGEN, GERMAN and BOSTON, MA / ACCESSWIRE / November 1, 2023 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced solid progress in its clinical vaccine development programs in COVID-19 and seasonal flu, conducted in collaboration with GSK.
- 11/01/2023
|
Why CureVac Stock Plunged Today
- CureVac previously failed to develop a successful COVID-19 vaccine, but filed a lawsuit last year against BioNTech alleging intellectual property violations. On Thursday a German court paused proceedings in the lawsuit while it awaits the outcome of BioNTech's challenge to the validity of that IP.
- 09/29/2023
|
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
- Regional Court Düsseldorf postpones infringement ruling on four intellectual property rights in lawsuit filed by CureVac against BioNTech Ruling on infringement to be provided latest once the validity of the intellectual property rights in suit has been determined by the relevant patent offices expected in 2024 As German infringement courts only suspend the proceedings if an intellectual property right is infringed and its validity has been challenged, it may be concluded that the Regional Court Düsseldorf found all four intellectual property rights to be infringed Ruling on infringement of a fifth intellectual property right scheduled for December 28, 2023 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 28, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the Regional Court Düsseldorf has decided to suspend proceedings on four intellectual property rights in the infringement lawsuit filed by CureVac against BioNTech.
- 09/28/2023
|
CureVac signals progress on mRNA flu vaccine
- CureVac NV CVAC, -3.85% said Tuesday that it has selected an mRNA flu vaccine candidate for continued clinical development, based on positive results from an early-stage study conducted in collaboration with GSK PLC GSK, +1.29%. The investigational vaccine provides broad antigen coverage against flu strains recommended by the World Health Organization and will advance to a phase 2 study, with dosing of the first study participant expected in the fourth quarter of this year, the company said in a release.
- 09/12/2023
|
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
- Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate mRNA constructs per candidate Best-performing candidate providing broad antigen coverage against WHO-recommended flu strains selected for Phase 2, following positive data from Phase 1 interim analysis Dosing of first Phase 2 participant anticipated in Q4 2023; Phase 2 to include older adults and standard-of-care comparison TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 12, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced selection of a promising vaccine candidate for continued clinical development based on positive data from an interim analysis of the ongoing Phase 1 part of a combined Phase 1/2 study, conducted in collaboration with GSK.
- 09/12/2023
|
3 Stocks to Buy For the COVID Resurgence
- The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting on updated COVID-19 vaccines at a meeting scheduled for September 12, 2023.
- 09/07/2023
|
Why Shares of CureVac Jumped This Week
- CureVac has an ongoing collaboration with GlaxoSmithKline. It just launched the first clinical study of a vaccine using CureVac's next-generation mRNA platform.
- 06/23/2023
|
Why CureVac Stock Leaped 12% Higher Today
- The European biotech delivered some promising news from the laboratory. It has dosed its first patient in a crucial phase 1 trial of its cancer vaccine.
- 06/20/2023
|
Peter Kolchinsky-led RA Capital's New Positions Feature CureVac, Mineralys, Pilant, Enliven Therapeu
- The Boston-based fund has emerged as a force to be reckoned with in the world of biotech investments.
- 05/23/2023
|
CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology
- CureVac NV said on Friday it had filed an expanded patent infringement claim against Pfizer Inc and BioNTech over the use of mRNA technology and that a U.S. court had granted its request to transfer the trial.
- 05/19/2023
|
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
- TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2023 / CureVac N.V. (Nasdaq:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourth quarter and full-year 2022 on Tuesday, April 25, 2023.
- 04/18/2023
|
UBS: CureVac has a ‘potentially competitive mRNA platform'
- CureVac's CVAC, +8.44% promising Phase 1 data for flu and COVID-19 vaccine candidates is a signal to investors that its messenger RNA technology is, in fact, competitive, according to UBS Securities analysts, who upgraded the company's stock to Buy from Neutral on Thursday. They also raised the price target to $18 from $8.
- 01/19/2023
|
UBS reveals a biotech stock that can nearly double from here
- Shares of CureVac BV (NASDAQ: CVAC) have already almost doubled year-to-date but a UBS analyst says the stock still has a lot more room to the upside.
- 01/19/2023
|
7 Biotech Stocks That Will Make You Rich in 10 Years
- If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they're seemingly one news item away from disaster.
- 01/18/2023
|
Why CureVac's Shares Jumped on Tuesday
- The stock rose for the third consecutive day.
- 01/10/2023
|
Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government's pandemic response
- A flurry of announcements relating to COVID vaccines dominated headlines on the pandemic on Monday, with Moderna telling investors it expects to generate some $5 billion in sales in 2023.
- 01/09/2023
|
CureVac shares surge after preliminary data on COVID-19 and flu shots
- CureVac CVAC, +29.47% shares rocketed 26% in premarket trade as the German company said preliminary data from its early stage trial for its COVID-19 and seasonal flu shots had positive results to advance to the next stage of clinical testing. CureVac is developing the shots with GlaxoSmithKline GSK, +1.28% GSK, -1.38%.
- 01/09/2023
|
CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines
- Amid a strong showing on Wall Street prior to the weekend, shares of CureVac (NASDAQ: CVAC ) stock popped dramatically northward on positive data for its coronavirus and flu vaccines. Preliminary clinical results demonstrate effectiveness against the omicron variant of Covid-19 along with the seasonal flu.
- 01/06/2023
|
CureVac N.V. (CVAC) Q3 2022 Earnings Call Transcript
- Start Time: 09:00 January 1, 0000 10:01 AM ET CureVac N.V. (NASDAQ:CVAC ) Q3 2022 Earnings Conference Call November 16, 2022, 09:00 AM ET Company Participants Franz-Werner Haas - CEO Pierre Kemula - CFO Ulrike Gnad-Vogt - Interim Chief Development Officer Ronald Plasterk - SVP Science & Innovation Sarah Fakih - VP Corporate Communications and IR Conference Call Participants Geoff Meacham - Bank of America Evan Wang - Guggenheim Jonathan Miller - Evercore Roy Buchanan - JMP Securities Zhiqiang Shu - Berenberg Operator Greetings, and welcome to CureVac Third Quarter and First Nine Months 2022 Financial Results and Business Update.
- 11/16/2022
|
CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022
- TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 10, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter of 2022 on Wednesday, November 16, 2022.
- 11/10/2022
|
Bet on These 4 Biotech Stocks With Bright Prospects
- New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.
- 09/28/2022
|
Jim Cramer's 'dirty dozen' stocks that underscore the carnage in the IPO market
- This year's market downturn has hit the IPO market hard.
- 09/27/2022
|
CureVac is focusing on mRNA cancer vaccines, CFO says
- Pierre Kemula, CureVac CFO, discusses the future of the technology.
- 09/20/2022
|
Here's Why CureVac N.V. (CVAC) is Poised for a Turnaround After Losing 20.9% in 4 Weeks
- CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
- 08/29/2022
|
BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims
- COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac.
- 07/26/2022
|
Wall Street Analysts Predict a 96% Upside in CureVac N.V. (CVAC): Here's What You Should Know
- The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 96.4% upside in the stock.
- 07/11/2022
|
BioNTech sued by CureVac over its mRNA technology
- CureVac (NASDAQ:CVAC) has filed a patent lawsuit in Germany against BioNTech (NASDAQ:BNTX) in what is one of the first court cases in which a company has sued another for using mRNA technology in developing a coronavirus vaccine. According to Germany-based CureVac, it will "assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to Covid-19 vaccine development", and is seeking "fair compensation" from BioNTech and two subsidiaries.
- 07/06/2022
|
CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech
- CureVac N.V. (NASDAQ: CVAC) has moved to assert its intellectual property rights, accumulated over two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development.
- 07/05/2022
|
CureVac Sues BioNTech Over mRNA and Covid Vaccines. Pfizer Stock Isn't Spared.
- CureVac says its intellectual property portfolio protects multiple inventions that are considered essential to Pfizer and BioNTech's Covid-19 vaccine.
- 07/05/2022
|
BioNTech stock falls after CureVac files suit, saying COVID vaccine infringes patents
- Shares of BioNTech SE BNTX, +5.63% fell 0.9% in premarket trading Tuesday, after CureVac N.V. CVAC, +4.63% filed in Germany a patent infringement suit against the biotechnology company.
- 07/05/2022
|
Wall Street Analysts See a 53% Upside in CureVac N.V. (CVAC): Can the Stock Really Move This High?
- The average of price targets set by Wall Street analysts indicates a potential upside of 53.3% in CureVac N.V. (CVAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 05/31/2022
|
CureVac NV (CVAC) CEO Franz-Werner Haas on Q4 2021 Results - Earnings Call Transcript
- CureVac NV (NASDAQ:CVAC ) Q4 2021 Earnings Conference Call April 28, 2022 9:00 AM ET Company Participants Sarah Fakih - VP Corporate Communications & IR Franz-Werner Haas - CEO Klaus Edvardsen - Chief Development Officer Pierre Kemula - CFO Conference Call Participants Douglas Buchanan - JMP Securities Eun Yang - Jefferies Zhiqiang Shu - Berenberg Operator Greetings. Welcome to the CureVac Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call.
- 04/28/2022
|
CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022
- TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourth quarter and full-year 2021 on Thursday, April 28, 2022.
- 04/22/2022
|
CureVac, GSK ink 'pandemic preparedness' agreement through 2029 with German government
- Shares of CureVac CVAC, -0.28% were up 0.6% in premarket trading on Monday after the company and GlaxoSmithKline GSK, +0.89% said they signed an agreement with the German government for pandemic preparedness that includes mRNA vaccines. As part of the agreement, Germany has access to CureVac's mRNA manufacturing until 2029.
- 04/11/2022
|
CureVac begins Phase 1 clinical trial for new COVID-19 vaccine
- Shares of CureVac CVAC, +0.47% were up 1.2% in premarket trading on Wednesday after the company said it dosed the first participant in a Phase 1 clinical trial for the new mRNA COVID-19 vaccine it's developing with GlaxoSmithKline GSK, -0.18% . The study is being conducted in the U.S. and is set to enroll 210 adults.
- 03/30/2022
|
CureVac (CVAC) Begins Influenza Shot Dosing in Phase I Study
- CureVac (CVAC) doses the first patient in a phase I study with investigational influenza vaccine candidate.
- 02/11/2022
|
CureVac starts Phase 1 trial for experimental flu shot developed with GSK
- Shares of CureVac CVAC, +5.06% gained 2.6% in premarket trading on Thursday after the company said it began dosing participants in a Phase 1 clinical trial assessing an experimental mRNA-based influenza vaccine it developed with GlaxoSmithKline GSK, -2.12% . The open-label study plans to enroll 240 adults.
- 02/10/2022
|
BofA Securities: there's hardly any upside in CureVac this year
- Shares of CureVac N.V. (NASDAQ: CVAC) closed nearly 15% down on Friday after BofA Securities said there isn't much in the books this year for shareholders of the German biopharmaceutical company.
- 01/21/2022
|
CVAC Stock Alert: Why Is Vaccine Maker CureVac Plunging Today?
- Amid broadly bearish market sentiment, investors in CureVac and CVAC stock are in selling mode, as this stock receives a downgrade. The post CVAC Stock Alert: Why Is Vaccine Maker CureVac Plunging Today?
- 01/21/2022
|
Why CureVac Stock Is Sinking Today
- Revisions to a shareholder agreement are causing the German vaccine maker's shares to fall.
- 01/14/2022
|
CureVac Outlines Upcoming Catalysts For Vaccine Programs
- Ahead of J.P. Morgan Healthcare Conference, CureVac BV (NASDAQ: CVAC) outlined the timeline for its vaccine programs.
- 01/10/2022
|
CureVac's (CVAC) CEO Franz-Werner Haas on Q3 2021 Results - Earnings Call Transcript
- CureVac's (CVAC) CEO Franz-Werner Haas on Q3 2021 Results - Earnings Call Transcript
- 11/19/2021
|
CureVac's COVID-19 Vax Shows Comparable Antibody Levels To Pfizer/BioNTech's Shot In Animal Study
- CureVac BV (NASDAQ: CVAC) has announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GlaxoSmithKline Plc (NYSE: GSK), in the journal Nature. Related Link: CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study.
- 11/18/2021
|
Why CureVac Shares Are Falling
- CureVac BV (NASDAQ: CVAC) shares are trading lower after the company and Bayer reportedly terminated their vaccine manufacturing partnership. More news came around 1:20 pm EDT after an SEC filing showed that dievini Hopp BioTech holding, which holds roughly 42% of outstanding CureVac shares, plans to sell some of its shares.
- 10/15/2021
|
CureVac ends development of Covid vaccine candidate
- CureVac CEO Franz Haas joins Closing Bell to discuss why his company discontinued the development of its Covid-19 vaccine. The company's stock fell today on the news.
- 10/12/2021
|
Why CureVac Stock Is Tumbling Today
- The company is throwing in the towel on its first-generation COVID-19 vaccine candidate.
- 10/12/2021
|
Why CureVac Shares Are Trading Lower Today
- CureVac NV (NASDAQ: CVAC) is trading lower Tuesday after the company announced it will focus its COVID-19 vaccine development towards the development of second-gen mRNA vaccine candidates in collaboration with GSK and to withdraw its first-gen vaccine from EMA approval process. CureVac estimates that the earliest potential approval of its first-gen vaccine would come in the second quarter of 2022.
- 10/12/2021
|
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
- - COVID-19 vaccine efforts to be re-allocated to accelerate the development of second-generation program in collaboration with GSK - First-generation vaccine candidate, CVnCoV, to be withdrawn from regulatory review due to potential overlap with approval timelines for a second-generation candidate TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 12, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA).
- 10/12/2021
|
CureVac stops development of its COVID-19 shot, will focus on new COVID-19 vaccine set for 2022
- Shares of CureVac CVAC, -1.37% tumbled 9.6% in premarket trading on Tuesday after the German biopharmaceutical company said it will scrap development of its COVID-19 vaccine candidate and instead focus on developing second-generation mRNA shots against COVID-19 with GlaxoSmithKline GSK, -1.21% . The existing purchase agreement with the European Commission is no longer in place.
- 10/12/2021
|
Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today
- Today, vaccine stocks are taking a massive hit as investors price in the potential effect of oral medications for Covid-19 on this sector. The post Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today appeared first on InvestorPlace.
- 10/01/2021
|
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
- CureVac BV (NASDAQ: CVAC) has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. The Company would terminate agreements with Celonic Group and Wacker, but existing production deals with Rentschler Biopharma and Novartis AG (NYSE: NVS) would remain unchanged.
- 09/14/2021
|
Why CureVac's Stock Is Down During Today's Session
- CureVac (NASDAQ:CVAC) shares are trading lower after the company announced its strategic decision to adjust the long-term footprint of the external European manufacturing network for its mRNA product pipeline. The decision was made in response to the reduced short-term peak demand for vaccines.
- 09/14/2021
|
Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines?
- It isn't likely.
- 08/27/2021
|
Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now
- The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet.
- 08/19/2021
|
CureVac Says Second Covid-19 Vaccine Was Better in Preclinical Test
- CureVac and partner GlaxoSmithKline say CureVac's second-generation Covid-19 vaccine was more effective than its first in a test with monkeys. CureVac's first vaccine was a disappointment.
- 08/17/2021
|
Boehringer Ingelheim Scraps Lung Cancer Program With CureVac
- CureVac NV (NASDAQ: CVAC) disclosed among the COVID-19 vaccine highlights that €465 million oncology partnership with Boehringer Ingelheim had been terminated. CureVac and Boehringer had been working to develop the mRNA cancer vaccine candidate since 2014, when CureVac received about €35 million upfront and nearly €430 million in promised milestones.
- 08/16/2021
|
Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX Stocks Today
- Today, investors in vaccine stocks are seeing a lot of red, as investors seem to be taking some risk off the table ahead of Fed tapering. The post Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX Stocks Today appeared first on InvestorPlace.
- 08/16/2021
|
CureVac stock gains after upbeat preclinical data on COVID-19 vaccine candidate on primates
- Shares of CureVac N.V. CURE, +0.48% gained 0.4% in morning trading Monday, but bucked the selloff in the biotechnology sector and the broader stock market, after the Germany-based company revealed upbeat preclinical data regarding its vaccine candidates against the coronavirus that causes COVID-19, in non-human primates.
- 08/16/2021
|
Nio Drops, CureVac Jumps as the Stock Market Slips
- Stocks look set for a lower open as the pace of growth in China slowed and Afghanistan fell back under Taliban control.
- 08/16/2021
|
CureVac Shares Increase Over 8% Pre-Market: Why It Happened
- The shares of CureVac N.V. (Nasdaq: CVAC) increased by over 8% pre-market.
- 08/16/2021
|
Can CureVac Win Market Share With Only 48% Vaccine Efficacy?
- CureVac aims to become one of Europe's big suppliers.
- 07/10/2021
|
Here's Why You Should Avoid CureVac Stock Like the Plague
- Funds will not be safe if invested in this coronavirus stock.
- 07/04/2021
|
Is CureVac a Bargain Bet on mRNA Vaccine Technology?
- CureVac shares have slipped more than 20% on bad news.
- 07/04/2021
|
Can CureVac Recover After Its Vaccine Setback?
- Investors' dreams of a third strong mRNA vaccine may be over.
- 07/03/2021
|
CureVac (CVAC) Announces Final Analysis of its COVID-19 Vaccine Study
- CureVac (CVAC) announces final analysis from its HERALD study on CVnCoV showing efficacy of 48%.
- 07/01/2021
|
CureVac to 'plow forward' with Covid vaccine despite disappointing results
- CureVac plans to continue work on its Covid-19 vaccine despite disappointing clinical trial results that showed the shot is just 48% effective.
- 07/01/2021
|
CureVac Stock Drops After Final Results Confirm Its COVID-19 Vaccine Trails Rivals
- The German biotech company CureVac BV (NASDAQ: CVAC) announced on Wednesday after hours the final results of its late-stage COVID-19 vaccine trial showing 48% effectiveness at preventing the disease, which is slightly higher than seen in a preliminary readout. But it lagged the efficacy rates of more than 90% shown by Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) and Moderna Inc's (NASDAQ: MRNA) mRNA shots.
- 07/01/2021
|
Why Shares Of CureVac Are Trading Higher On Wednesday
- CureVac (NASDAQ: CVAC) shares are trading higher after the company announced the appointment of Dr. Malte Greune as COO and the transition of Dr. Florian von der Mülbe to lead accelerated development of the RNA printer. Dr. Greune joins the company from Sanofi-Aventis Deutschland, where he held multiple management positions.
- 06/30/2021
|
Without a Coronavirus Vaccine Of Its Own, Is There Any Hope For CureVac Stock?
- Things are looking bleak right now, but they might improve with enough time.
- 06/29/2021
|
Why CureVac Shares Are Trading Lower Today
- CureVac BV (NASDAQ:CVAC) shares are trading lower by 3.6% at $56 after the CDC said preliminary findings suggest the observed reports of heart inflammation after mRNA COVID-19 vaccines are greater than expected. CureVac a clinical-stage biopharmaceutical company, developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people.
- 06/23/2021
|
Could CureVac Be a Millionaire-Maker Stock?
- CureVac's first COVID vaccine candidate disappointed investors. But a second one looks promising.
- 06/23/2021
|
How Pfizer and Moderna Could Profit Big-Time From AstraZeneca's and CureVac's Challenges
- Bad news for AstraZeneca and CureVac should mean more good news for Pfizer and Moderna.
- 06/23/2021
|
Germany's BaFin looking into possible insider trading of CureVac shares
- German financial watchdog BaFin is investigating possible insider trading of vaccine maker's CureVac shares, which fell after the biotech firm announced its COVID-19 vaccine proved only 47% effective, Rheinische Post newspaper reported on Monday.
- 06/21/2021
|
Why Is Everyone Talking About CureVac Stock?
- This coronavirus vaccine developer just hit a massive stumbling block.
- 06/21/2021
|
CureVac Says Its Not Giving Up on a Covid-19 Vaccine and The Shares Are Soaring.
- The CEO of the German company said on Thursday that CureVac hoped its vaccine candidate could still be of use after trial data showed it was a failure.
- 06/18/2021
|
12 Words From CureVac's CEO That Could Mean Billions for Moderna and Pfizer
- The news may reinforce Moderna's and Pfizer's vaccine-market dominance.
- 06/18/2021
|
Curevac shares climb 10%; CFO says not giving up on COVID-19 vaccine
- Shares of Curevac rose 10% in premarket trading on Friday. Shares of the German biotech have lost 48% this week after the company said a late-stage clinical trial of its COVID-19 vaccine was only 47% effective.
- 06/18/2021
|
Tesla Partner CureVac Says Will Find 'Sweet Spot' For COVID-19 Vaccine Despite Disappointing Data
- CureVac N.V.'s (NASDAQ: CVAC) Chief Financial Officer Pierre Kemula is optimistic its COVID-19 vaccine could still be offered to certain age groups or as a booster, the Financial Times reported on Thursday.
- 06/18/2021
|
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
- So what did the stock market do today? All eyes were on a World Bank decision and big moves in RIDE and CVAC stocks.
- 06/17/2021
|
CureVac (CVAC) Plummets on Disappointing COVID-19 Vaccine Data
- CureVac (CVAC) down as it announces that its first-generation COVID-19 vaccine candidate, CVnCoV, did not meet the prespecified statistical success criteria in a phase IIb/III study.
- 06/17/2021
|
CureVac collapses 45% after disappointing results from COVID-19 vaccine trial
- CureVac NV (NASDAQ: CVAC) slipped about 45% in the stock market on Thursday morning as the company said the late-stage trial showed its candidate COVID-19 vaccine to be only 47% effective, raising questions on the German biotech's agreement with the European Union to deliver hundreds of millions of doses of its vaccine (CVnCoV). CureVac's shot […] The post CureVac collapses 45% after disappointing results from COVID-19 vaccine trial appeared first on Invezz.
- 06/17/2021
|
Why CureVac Stock Is Getting Crushed Today
- The biotech's COVID-19 vaccine candidate no longer appears to be viable.
- 06/17/2021
|
Options Traders Swam Spiraling CureVac Stock
- One of the worst stocks on the Nasdaq this morning, the shares of CureVac BV (NASDAQ:CVAC) are spiraling, last seen down 48.8% to trade at $48.49.
- 06/17/2021
|
CureVac shares drop 45% after disappointing Covid vaccine results
- Shares in CureVac plummeted on Thursday after the German biotech company said that interim trial results showed its experimental Covid-19 vaccine was only 47% effective in preventing symptomatic disease.
- 06/17/2021
|
Morning Stock Movers: CureVac, Citigroup, Newmont
- Jun.17 -- Bloomberg's Romaine Bostick runs down the biggest moving stocks in today's pre-market trading.
- 06/17/2021
|
CureVac tumbles 41% in premarket on COVID-19 vaccine disappointment
- Shares of CureVac fell 42% in premarket trading on Thurdsay, a day after the German biotech said its COVID-19 vaccine was 47% effective in preventing the disease. CureVac's study, conducted in 10 countries and involving 40,000 people, showed the vaccine's struggle against a "fast changing environment" of at least 29 COVID-19 variants, with the original coronavirus strain "almost completely absent.
- 06/17/2021
|
German biotech CureVac's stock plunges 50% after its COVID-19 vaccine candidate failed a clinical trial
- Interim analysis of data from about 40,000 volunteers showed the biotech's jab is only 47% effective, falling short of the study's criteria.
- 06/17/2021
|
Coronavirus tally: Global cases of COVID-19 top 177 million and CureVac vaccine is just 47% effective
- The global tally for the coronavirus-borne illness headed above 177 million on Thursday, according to data aggregated by Johns Hopkins University, while deaths climbed above 3.8 million. The U.S. continues to lead the world in total cases at 33.49 million, while deaths total 600,653.
- 06/17/2021
|
CVAC Stock Price Falls Over 45% Pre-Market: Why It Happened
- The stock price of CureVac BV (NASDAQ: CVAC) fell by over 45% pre-market. This is why it happened.
- 06/17/2021
|
Tesla-Backed CureVac Plunges On Underwhelming COVID-19 Vaccine Efficacy Data
- German vaccine developer, CureVac N.V. (NASDAQ: CVAC), may not be as fortunate as its domestic peer BioNTech SE (NASDAQ: BNTX), which along with its U.S. partner Pfizer, Inc. (NYSE: PFE), has found resounding success with its vaccine program.
- 06/17/2021
|
CureVac stock drops more than 50% on news trial COVID vaccine 47% effective
- Shares of Curevac NV tanked more than 50% in the extended session Wednesday after the pharma company said its trial COVID-19 vaccine showed an efficacy of 47% against the illness.
- 06/16/2021
|
CureVac's COVID-19 shot just failed in a large trial, a major setback for the Gates-backed biotech
- CureVac's stock tanked after the announcement. The German biotech blamed variants in a press release.
- 06/16/2021
|
CureVac: The Moment Of Truth Is Delayed Until August
- CVAC's COVID-19 vaccine may not be reviewed by regulatory authorities until August.
- 06/14/2021
|
RMED, HOOK, JZXN, ACRS, OPRA, CVAC Stock Prices Fall Intraday
- The stock prices of RMED, HOOK, JZXN, ACRS, OPRA, and CVAC have fallen noticeably today. These are the details.
- 06/08/2021
|
Could CureVac Be a Millionaire-Maker Stock?
- This biotech's coronavirus vaccine candidate could be the next to hit the market -- but a lot of its potential success has been priced in.
- 06/08/2021
|
7 Best Vaccine Stocks for Their Pipeline Potential
- These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer. The post 7 Best Vaccine Stocks for Their Pipeline Potential appeared first on InvestorPlace.
- 06/03/2021
|
Top COVID-19 Vaccine Stories of May Put Biotech ETFs in Focus
- Let's take a look at some top coronavirus vaccine stories of May and the possible impact they can have on biotech ETFs.
- 06/01/2021
|
CureVac's COVID-19 Vaccine Is Safe, But Efficacy Not Yet Disclosed
- CureVac BV (NASDAQ: CVAC) said its first-generation COVID-19 vaccine candidate had passed its first interim analysis, but it was not yet ready to share efficacy data. The company said an independent Data Safety Monitoring Board found no safety concerns for the vaccine, dubbed CV2CoV.
- 06/01/2021
|
CureVac (CVAC) Announces Positive Data on COVID-19 Vaccine
- CureVac (CVAC) announces the continuation of its COVID-19 vaccine study following the first interim analysis in 59 eligible COVID-19 cases.
- 05/31/2021
|
Moderna: Stuck Between CureVac And A Hard Place
- Moderna: Stuck Between CureVac And A Hard Place
- 05/28/2021
|
Novartis (NVS) & Molecular Partners Initiate Study for COVID-19
- Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.
- 05/27/2021
|
CureVac's Covid-19 Vaccine Has Important Role to Play in Fighting Variants, CEO Says
- The European regulator started a rolling review of the shot in February based on preliminary results from laboratory studies and early clinical studies in adults.
- 05/26/2021
|
CureVac's COVID vaccine has important role to play in fighting variants, CEO says
- CureVac's CEO said the company's experimental COVID-19 vaccine can still play an important role in the pandemic fight given the “rapid spread” of concerning variants.
- 05/26/2021
|
Two COVID-19 vaccine makers in the news: CureVac and Moderna expanding production
- With COVID-19 vaccines still scarce around the world, companies are announcing plans to expand production so as to speed up vaccine distribution worldwide. CuraVac N.V.
- 05/24/2021
|
7 Global Stocks That Are Worth Adding to Your Portfolio
- Here's a list of seven global stocks that can be added to the portfolio for exposure to growth themes from different regions. The post 7 Global Stocks That Are Worth Adding to Your Portfolio appeared first on InvestorPlace.
- 05/20/2021
|
CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study
- CureVac N.V. (NASDAQ: CVAC) and GlaxoSmithKline Plc (NYSE: GSK) have released positive early data from a preclinical study of its second-generation COVID-19 vaccine with signs that the candidate could also provide good protection against some variants of the virus.
- 05/13/2021
|
What's Up WIth BioNTech Stock And CureVac Stock Today?
- BioNTech SE - ADR (NASDAQ: BNTX) shares were trading higher by 8.27% at $198.80 in Monday's premarket session after the company announced a Chinese joint venture to make 1 billion COVID-19 vaccine doses. BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases including COVID-19.
- 05/10/2021
|
CureVac Could Soon Join The Fight Against COVID-19
- CVAC is close to getting its COVID-19 vaccine approved in Europe. Its mRNA technology could potentially compete with PFE and MRNA.
- 05/10/2021
|
CureVac's Vaccine Might Protect Against the South African Variant
- The promising data in mice needs to translate into humans.
- 05/01/2021
|
Best Biotech Stocks & ETFs for mRNA, Gene Editing
- Here is what you should know about investing in these life changing technologies.
- 04/29/2021
|
Novartis CEO says could boost CureVac vaccine production, if needed
- Novartis is scaling up facilities to make COVID-19 vaccine doses for German drugmaker CureVac and could boost production beyond levels agreed so far, Chief Executive Vas Narasimhan said on a conference call on Tuesday.
- 04/27/2021
|
CureVac's Potential Has Wall Street Sending Mixed Signals
- The biotech still has a long way to go to prove itself and justify its current stock valuation.
- 04/26/2021
|
2 Reasons This COVID Vaccine Latecomer Could Gain Major Market Share
- A big market is in big need of more vaccines.
- 04/21/2021
|
CureVac in Talks With U.S. Over Next-gen Covid Shot: CEO
- Apr.16 -- CureVac CEO Franz-Werner Haas says the company aims to produce 300 million doses of their mRNA-based vaccine in 2021 and is in discussions with the U.S. and other countries about supplying next-generation Covid-19 vaccines capable of targeting multiple strains of the coronavirus.
- 04/18/2021
|
CureVac to Release Results of Covid Vaccine Trials
- Apr.15 -- Kempen & Co Equity Analyst of Life Science Ingrid Gafanhao speaks to Bloomberg's Alix Steel about the Curevac Covid-19 vaccine and it's expected release now that variants are being taken into account. She speaks on "Bloomberg Markets: European Close".
- 04/15/2021
|
CureVac says it is on track with COVID-19 vaccine as it posts earnings update
- The German company, which went public last August, said its vaccine is in the final stage of clinical development.
- 04/15/2021
|
Covid vaccine maker CureVac hopes shot will get EU approval in June
- The U.K. and EU have pre-ordered up to 455 million doses of CureVac's mRNA vaccine, subject to regulatory approval.
- 04/08/2021
|
CureVac Taps Celonic For COVID-19 Vaccine Production
- CureVac BV (NASDAQ: CVAC) has partnered with Celonic Group, a Contract Development, and Manufacturing Organization, to produce CureVac's mRNA-based COVID-19 vaccine candidate, CVnCoV. The commercial supply agreement includes manufacturing of the mRNA drug substance and LNP formulation of the bulk drug product at Celonic's manufacturing facility in Heidelberg, Germany.
- 03/30/2021
|
CureVac Expands Late-Stage Trials Of COVID-19 Vaccine Candidate
- CureVac BV (NASDAQ: CVAC) plans to expand and further specify the protocols of its ongoing late-stage clinical trials with CVnCoV, its COVID-19 vaccine candidate. CVnCoV efficacy is currently being evaluated in the pivotal HERALD Phase 2b/3 trial in Europe and Latin America.
- 03/22/2021
|
Novartis (NVS) & CureVac Collaborate for COVID-19 Vaccine
- Novartis (NVS) will manufacture the mRNA and bulk drug product for CureVac's COVID-19 vaccine candidate.
- 03/05/2021
|
Novartis Lends Support To Manufacture CureVac's COVID-19 Shots
- Swiss Pharma giant Novartis AG (NYSE: NVS) has agreed to help CureVac BV (NASDAQ: CVAC) produce its experimental COVID-19 vaccine, known as CVnCoV. Novartis plans to manufacture the mRNA molecules that the vaccine is based on and “bulk drug product” for up to 50 million doses by the end of 2021 and up to a further 200 million doses in 2022.
- 03/04/2021
|
COVID-19 Vaccine Updates: US Strikes 100M-Dose Supply Deals With Moderna, Pfizer, EU Starts Rolling Review Of CureVac Vaccine
- Coronavirus vaccine news supply deals and a regulatory filing are in the headlines in Friday's trading session. US Secures More Vaccine Doses: Moderna Inc (NASDAQ: MRNA) and Pfizer Inc. (NYSE: PFE), the two companies that have received emergency use authorization for vaccine candidates in the U.S., confirmed supply deals with the federal government.
- 02/12/2021
|
CureVac's stock is up 6% as it begins regulatory process for its COVID-19 vaccine in the E.U.
- Shares of CureVac gained 6.0% in premarket trading on Friday after the company said it started a rolling submission for its experimental mRNA-based COVID-19 vaccine in the European Union. The vaccine is currently being tested in a Phase 3 clinical trial in Europe and Latin America.
- 02/12/2021
|
CureVac working on a second generation vaccine to combat Covid variants, CEO says
- CureVac CEO Franz-Werner Haas discusses the firm's plans to tackle new Covid-19 variants.
- 02/12/2021
|
UK Government teams up with CureVac to find mutant COVID-19 vaccine
- The UK government has said it is to join forces with German group CureVac BV (NASDAQ:CVAC) to develop vaccines capable of dealing with mutations in the coronavirus (COVID-19) virus. Britain has initially ordered 50mln doses of any vaccine developed through the collaboration, which will see the company work with the UK Vaccine's Taskforce.
- 02/07/2021
|
U.S. IPO Week Ahead: Bumble's Billion-Dollar Deal Leads A Buzzy 11 IPO Week
- U.S. IPO Week Ahead: Bumble's Billion-Dollar Deal Leads A Buzzy 11 IPO Week
- 02/06/2021
|
CureVac Shares Gain After UK Backs Company's Vaccine Development Efforts For COVID-19 Variants
- The U.K. has entered into a collaboration accord with CureVac NV (NASDAQ: CVAC) to develop messenger ribonucleic acid (mRNA)-based vaccine candidates against COVID-19 variants. CureVac will deliver an initial supply of 50 million doses of any resulting vaccine candidates.
- 02/05/2021
|
CureVac to develop new variant vaccines for the U.K.
- Shares of CureVac gained 7.7% in trading on Friday after the company said it plans to develop COVID-19 vaccine candidates that can prevent infection with new variants as part of an agreement with the United Kingdom. The U.K. has already agreed to take 50 million doses of the yet-to-be-identified variant vaccines.
- 02/05/2021
|
CureVac Joins GlaxoSmithKline to Make Next-Gen Covid Shot
- Feb.03 -- CureVac has joined forces with GlaxoSmithKline Plc to create a next-generation Covid mRNA shot that could help protect against multiple variants of the pathogen, and it's extended a partnership with Bayer AG to allow the German pharma giant to produce CureVac's vaccine. CureVac CEO Franz-Werner Haas spoke on "Bloomberg Markets.
- 02/03/2021
|
GSK and CureVac are making 'next-generation' vaccines that they say can tackle multiple COVID-19 variants at once
- UK pharma giant GlaxoSmithKline (GSK) and German biotech CureVac plan to co-develop "next generation" vaccines that could work against multiple coronavirus variants at once, the companies announced Wednesday. The vaccines could be available in 2022, subject to authorization, and could work as a booster if immunity from another vaccine wanes, or for people who haven't yet been immunized, the companies said.
- 02/03/2021
|
GSK and CureVac join forces to develop vaccines targeting new COVID-19 variants
- GSK and CureVac said their approach could potentially tackle multiple coronavirus strains in one vaccine shot
- 02/03/2021
|
CureVac aims to raise $450 million through public offering
- Shares of CureVac were down 3.1% in premarket trading on Thursday after the German company said it aims to raise $450 million through a follow-up public offering. CureVac, which went public in August, priced the follow-on public offering of 5 million shares at $90.00 per common share.
- 01/28/2021
|
CureVac: Smart Money Is On COVID-19 Vaccine Approval
- CureVac shares currently trade at $100.6 - down from nearly $150 in early December. The mRNA specialist IPO'd at a price of just $16 in August last year, but shares have spiked in anticipation of an approval for its COVID-19 vaccine.
- 01/15/2021
|
CureVac partners with Bayer to accelerate vaccine production
- Franz-Werner Haas, CureVac CEO says it has initiated a phase 2b-3 trial and expects to enroll 35,000 people in Europe and Latin America. He joins 'Closing Bell' to discuss.
- 01/12/2021
|
CureVac (CVAC) Up on Deal With Bayer for COVID-19 Vaccine
- CureVac (CVAC) gains on a collaboration agreement with Bayer (BAYRY) for further development and supply of its COVID-19 vaccine candidate, CVnCoV.
- 01/08/2021
|
Why Coronavirus Stock CureVac Crushed It on Thursday
- The coronavirus vaccine developer announced a new partnership with a major player on the global pharmaceutical scene.
- 01/07/2021
|
CureVac Secures Bayer as a Partner for Its Coronavirus Vaccine
- Sometimes you need a little help from a big brother.
- 01/07/2021
|
CureVac Shares Rip Higher On Coronavirus Vaccine Deal With Bayer
- CureVac BV (NASDAQ: CVAC) shares have received a nice lift and breached the $100 level for the first time in the new year. What Happened: German coronavirus vaccine maker CureVac said Thursday it has signed a collaboration and services agreement with German chemicals company Bayer AG (Pink: BAYRY) for the further development, supply and territorial operations of CureVac's CVnCoV.
- 01/07/2021
|
CVAC Soars on Bayer COVID-19 Vaccine Collaboration
- The shares of CureVac BV (NASDAQ:CVAC) are soaring this morning, up 18.5% at $102.88 at last check.
- 01/07/2021
|
IBD Announces 100 Best Companies of 2020
- LOS ANGELES--(BUSINESS WIRE)---- $CVAC #COVID19--Investor's Business Daily (IBD), a leading financial news and research organization, today announced its list of the 100 Best Companies of 2020. Companies were selected based on stock performance throughout a year heavily influenced by the COVID-19 pandemic. Tesla claimed the top spot, as tech companies excelled, while a full quarter of the 100 Best Companies were biotechs. Despite the unstable environment, approximately one-third of the 100 Best Companies went pub
- 01/07/2021
|
CureVac Forms Covid-19 Vaccine Alliance With Bayer. The Stock Is Surging.
- The German biotech struck a deal with chemicals-and-drugs giant Bayer to accelerate the development and supply of its Covid-19 vaccine candidate.
- 01/07/2021
|
CureVac strikes COVID-19 vaccine alliance deal with Bayer -Bild
- German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, daily Bild reported.
- 01/06/2021
|
4 Small COVID-19 Vaccine Makers to Look Out for in 2021
- Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.
- 12/18/2020
|
How CureVac Is Advancing in the Fight Against COVID-19
- CureVac N.V. (NASDAQ: CVAC) advanced in the fight against COVID-19 by beginning enrollment in its midstage vaccine candidate study.
- 12/14/2020
|
CureVac starts Phase 3 clinical trial of its Covid-19 vaccine candidate
- Tübingen-based CureVac said the Phase 3 trial will include more than 35,000 volunteers in Europe and Latin America
- 12/14/2020
|
Is It Too Late to Get in on This Millionaire-Maker Stock?
- A biotech that no one has heard of has been making a few investors rich for much of 2020.
- 12/12/2020
|
2 Surprising Coronavirus Vaccine Stocks to Buy Right Now
- If we judge by return on investment, these two mid-cap biotechs may be the ultimate winners of the coronavirus vaccine race.
- 12/03/2020
|
COVID Vaccine Stocks Update: Where Things Stand Now
- Here's what you need to know about all of the leaders in the coronavirus vaccine race.
- 12/02/2020
|
This Under-the-Radar COVID Vaccine Stock Has a Tesla Tie-In
- And it's not too far behind coronavirus vaccine leaders Pfizer and Moderna.
- 11/27/2020
|
Is There Room for Latecomers to the COVID-19 Party?
- Despite multiple treatments, vaccines, and tests for COVID-19 developed by leading competitors, Sorrento's CEO Henry Ji thinks the company still has an opportunity to thrive.
- 11/21/2020
|
Exclusive: EU could pay over $10 billion for Pfizer and CureVac vaccines - source
- The European Union could pay more than $10 billion to secure hundreds of millions of doses of the vaccine candidates being developed by Pfizer-BioNTech and CureVac, an EU official involved in the talks told Reuters.
- 11/20/2020
|
Enough Pharma Capacity to Vaccinate World by End of 2021: CureVac CEO
- Nov.18 -- CureVac Chief Executive Officer Franz-Werner Haas discusses the progress on the biopharmaceutical company's Covid-19 vaccine and scale-up for its production on “Bloomberg Surveillance.”
- 11/18/2020
|
German vaccine maker CureVac ramps up capacity to 300 million COVID-19 doses in 2021
- CureVac expects to announce partnerships with vaccine developers and manufacturers in coming weeks to ramp up capacity of its potential vaccine candidate.
- 11/17/2020
|
3 mRNA Coronavirus Vaccine Stocks to Check Out That Aren't Pfizer, BioNTech, or Moderna
- Great efficacy results for mRNA COVID-19 vaccines so far could bode well for these three stocks.
- 11/17/2020
|
3 Best Biotech Stocks to Buy Right Now
- Biotech is on every investor's mind as we move closer and closer to a successful vaccine for the coronavirus. Here are three contenders for your portfolio.
- 11/14/2020
|
CureVac Rallies On Interim Phase 1 Data For COVID-19 Vaccine Candidate: What You Need To Know
- German biopharma CureVac BV (NASDAQ: CVAC) — which is developing an mRNA vaccine against the novel coronavirus — was rallying Tuesday following the release of detailed interim Phase 1 data for the investigational vaccine. What Happened: Interim analysis of data from the dose-escalation Phase 1 study in healthy volunteers showed that two doses of the vaccine candidate CVnCoV, ranging from 2 μg to 12 μg per dose and administered 28 days apart, were safe, according to a preprint available on medRxiv.
- 11/10/2020
|
CureVac's stock is up 8% as it shares additional Phase 1 data about its COVID-19 vaccine candidate
- Shares of CureVac gained 8.0% in premarket trading on Tuesday after the company disclosed additional clinical data about how its COVID-19 vaccine candidate is performing in a Phase 1 clinical trial. Interim data from an early-stage clinical trial was published Tuesday as a preprint, according to the U.S.-listed German company, which is running clinical trials for its experimental RNA vaccine in Belgium and Germany.
- 11/10/2020
|
CureVac Reports Early-Stage Data for Its Coronavirus Vaccine Candidate
- Participants in the phase 1 clinical trial mounted an immune response after being inoculated with CVnCoV.
- 11/02/2020
|
CureVac Posts Positive Early Data For Its Covid-19 Vaccine Candidate
- Recent hot IPO CureVac reported positive Phase 1 clinical trials data for its Covid-19 vaccine candidate, which is among a number based on mRNA technology. CVAC stock rose on the news.
- 11/02/2020
|
CureVac's COVID-19 vaccine shows immune response in Phase 1 trial
- German biotech CureVac said advanced clinical trials are on track to launch by the end of 2020.
- 11/02/2020
|
Investors Betting on a Coronavirus Vaccine Better Know Who Gets First Dibs in Global Pact
- The World Health Organization is managing a global vaccine program without U.S. participation, and it could have a big impact for investors.
- 10/27/2020
|
U.S. IPO Week Ahead: No IPOs, But Plenty Of Potential Launches In The Short Holiday Week
- Just one SPAC is scheduled for the week ahead. More SPACs may join the IPO calendar, and another wave of new filings will likely hit after Labor Day as well.
- 09/06/2020
|
Wall Street Breakfast: The Week Ahead
- Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- 09/06/2020
|
Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 09/05/2020
|
Coronavirus Vaccine Roundup, Early September
- Taking a looking at the COVID-19 vaccine development landscape across various classes, including viral vectors, genetic vaccines, recombinant protein vaccines, attenuated virus vaccines, inactivated virus vaccines, and virus-like particles.
- 09/04/2020
|
9 Reasons Why The Race For Major COVID-19 Vaccine Revenues Has Greatly Narrowed
- The huge amount of Operation Warp Speed funding for its six vaccines has helped them become somewhat dominant leaders in the race for a sizable share of the market.
- 09/02/2020
|
Novavax: COVID-19 Gave It Fuel, But It's Running Near Empty
- NVAX had run over 4,000% YTD at its peak. COVID-19 vaccine hype is giving it some much-needed fuel after failing two late-stage clinical trials in 2016 and 2019.
- 08/31/2020
|
COVID-19: The Real Results Are A Long Way Away
- Hope for a successful vaccine by the winter is fueling trials at a record pace. WHO data shows that there are 38 candidates in clinical trials, but only 8 are in Phase 2 and Phase 3.
- 08/19/2020
|
Stocks on the Move: Curevac gains 249% on first day of trading, Nvidia stock rises on Susquehanna target boost
- The On the Move panel discuss today's Stocks on the Move: Curevac and Nvidia.
- 08/17/2020
|
CureVac Stock Soared 249% on Its First Day of Trading. Here’s What It’s Doing for an Encore.
- Shares of CureVac, which specializes in the messenger RNA technology that is the basis of many of the leading Covid-19 vaccine programs, is set to soar on the second trading day.
- 08/17/2020
|
CureVac's Impressive Debut, And Other News: The Good, Bad And Ugly Of Biopharma
- CureVac makes impressive debut, stock jumps 175%. Masimo receives FDA clearance for mechanically ventilated patients.
- 08/17/2020
|
Wall Street Breakfast: Trump Eyeing More Chinese Firms For Possible Action
- Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- 08/17/2020
|
New Zealand Delays Elections; U.S. Cases Slow: Virus Update
- (Bloomberg) -- New Zealand delayed its national election by four weeks over concerns the outbreak could disrupt the campaign and balloting. U.S. deaths exceeded 1,000 for the fifth consecutive day. Another 47,813 cases were reported nationwide, a decrease from the previous week’s daily average. Texas hospitalizations fell to a seven-week low. Italy told nightclubs to close, matching a similar directive by Spain on Friday. France’s public health agency warned that all of the country’s Covid-19 indicators are trending upward.Key Developments:Global Tracker: Global cases top 21.5 million; deaths pass 772,000How $50,000-a-year private schools plan for Covid: NYC ReopensFirst into the virus slump, China is proving the fastest outRussia’s new Sputnik launch raises risks in dash for Covid shotsIndia’s virus testing system is ‘like flipping a coin’Rubber-glove boom spurred by pandemic creates billionaireSubscribe to a daily update on the virus from Bloomberg’s Prognosis team here. Click CVID on the terminal for global data on coronavirus cases and deaths.Texas Hospitalizations Down (6:50 a.m. HK)Coronavirus patients in Texas hospitals fell to 6,267, the lowest in seven weeks. Another 143 deaths were reported, to just under a total of 10,000 fatalities. The state added 6,204 new cases, fewer than the previous day, for a total of 535,042.New Zealand Postpones Election (6:23 a.m. HK)New Zealand Prime Minister Jacinda Ardern has delayed the general election by four weeks until Oct. 17 as a community outbreak of Covid-19 worsens.Ardern said Monday she delayed the election from Sept. 19 after consultation with other political parties, to provide certainty to voters.A fresh outbreak of the virus in Auckland has seen the largest city locked down since Aug. 12 with people urged to stay home and consumer-facing businesses shut -- denting consumer confidence while making political campaigning and fund-raising impossible. The city, home to almost one third of the nation’s 5 million citizens, is a key battleground for Ardern as her Labour Party seeks a second term.Brazil Cases, Deaths Down (5:50 p.m. NY)Brazil reported 23,101 cases, down from 41,576 the previous day, for a total of 3,340,197. Another 620 deaths, down from 709 the day before, were added in the nation hit worst by the pandemic after the U.S. Total deaths are now 107,852.Virus Clusters Spread at University of North Carolina (5:15 p.m. NY)A new cluster of Covid-19 cases has broken out at a University of North Carolina residence, the fourth in the last three days, the Daily Tar Heel reported on Sunday.A university spokesman said it would not say how many students were infected, according to the student newspaper. The university defines as five or more cases in “close proximity.”Residents of infected halls received an email saying that testing and tracing protocols are in place and no additional action was required, the newspaper reported.Another Georgia High School Closes (2:58 p.m.)A third high school in a Georgia county hit by a Covid-19 outbreak said it would close after 25 students tested positive and 500 were quarantined, the Atlanta Journal-Constitution reported. The school district expects more of the 1,800 students to be quarantined once testing is completed.Another high school in Cherokee county, Etowah, made national headlines after students posted pictures of maskless crowds of students -- and was then closed after 59 students tested positive.Hard-hit Georgia has been a battleground during the pandemic. Governor Brian Kemp insisted on an early reopening, then sued localities including Atlanta for requiring face masks. He withdrew that lawsuit last week, and on Saturday signed an executive order allowing for local mask ordinances while exempting private property from enforcement or fines.California ICU Trend Reaches Seven-Week High (2:05 p.m. NY)California added 7,873 new cases -- compared with the 14-day average of 8,029 -- bringing the total to 621,562. Deaths rose by 77 to 11,224.While the number of hospital patients fell to the lowest level since the end of June, the percentage of those in ICU increased to 31.8% based on a five-day average, the highest since late June, according to data on the state’s health department’s website.France Headed for Masks in Offices (1:48 p.m. NY)France reported 3,015 coronavirus cases in 24 hours, marking the second straight day with more than 3,000 new infections. One additional death was reported.“The situation is worrying: All indicators continue to increase and the transmission of the virus is on the rise,” the French public health agency said in a statement.French Labor Minister Elisabeth Borne will propose Tuesday that masks be required in businesses by September in places where people work together in an enclosed space, she said in an interview with Journal du Dimanche.She cited meeting rooms and common areas as places where masks would be required, and said she will discuss with the Health Ministry whether they’ll be needed in open-plan offices.Italy Closes Nightclubs, Widens Mask Orders (1:30 p.m. NY)The Italian government ordered nightclubs to close and broadened rules on wearing protective masks after talks Sunday with regional leaders.Dances in nightclubs, indoors and in the open will be suspended, Health Minister Roberto Speranza said in a Facebook post. Wearing masks will be compulsory from 6 p.m. to 6 a.m. in public spaces, including squares and streets where crowds can gather. Spain closed nightclubs on Friday.“We cannot nullify the sacrifices made in the past months,” Speranza wrote. Italy already requires people to wear face coverings on public transport and in shops among other indoor locations.Italy reported 479 new coronavirus cases Sunday after 629 a day earlier, which was the most since late May. The trend has been driven in part by Italians returning from vacations abroad.Ireland Warned on Possible New Curbs (1:07 p.m. NY)Irish Chief Medical Officer Ronan Glynn said authorities “will make any necessary recommendations” to the government to ensure a safe reopening of health-care services and schools.While the country’s phased reopening has allowed people to socialize again, “some are doing this recklessly,” Glynn said in a statement. Ireland reported 66 new Covid-19 cases on Sunday, compared with 200 a day earlier.Arizona Cases, Deaths Fall (11:40 a.m. NY)Arizona reported 883 cases, fewer than the previous day and in line with the average 0.5% daily increase from the week before. Total cases are 193,537. Reported deaths fell to 14, from 69 the day before, for a total of 4,506.Florida Cases, Deaths Slow (11 a.m. NY)Florida reported 573,416 cases, up 0.7% from a day earlier, compared with an average increase of 1.1% in the previous seven days. Deaths among Florida residents reached 9,452, an increase of 107, according to the state health department report, which includes data through Saturday. The state has reported four days in the last week with more than 200 deaths.New York Reports Fewer Cases (10:15 a.m. NY)New York reported 607 cases, a 0.1% rise compared with an average 0.2% increase from the previous seven days. Another six deaths were recorded, Governor Andrew Cuomo said in a tweet. Hospitalizations remained steady, and positive-test results stayed under 1%, he said.N.J. Governor Backs Biden Mask Plan (10 a.m. NY)New Jersey Governor Phil Murphy said on Sunday he supports Joe Biden’s suggestion that each state should require its people to wear face masks to curb the spread of the deadly coronavirus that continues to ravage the U.S.“The science and the data and the facts are unequivocal,” Murphy, who is also a co-chair for the Democratic National Committee’s presidential convention, said in an interview on Fox News Sunday with Chris Wallace. “I think we could accelerate dramatically driving this virus into the ground. It’s been a big weapon for us in New Jersey, but as a nation we’re only as strong as our weakest link. To have a national strategy I think would be a game changer.”Last month Murphy signed an executive order requiring people to wear face coverings when they are outside in public spaces and can’t socially distance.U.K. Cases Pass 1,000 Again (9:55 a.m. NY)U.K. cases increased by more than 1,000 for the sixth consecutive day and five more people died of Covid-19, according to figures from the Department of Health and Social Care.The latest daily figure for deaths, which includes all those who tested positive for coronavirus in the U.K. and then died within 28 days of that test, rose from three reported Saturday, according to the department. The number of new cases was up from 1,012 Saturday.U.S. Rise in Cases Below 7-Day Average (8 a.m. NY)U.S. cases increased by 47,813, a 0.9% rise on the day. That’s lower than the 1% increase over the previous week, according to data compiled by Johns Hopkins University and Bloomberg. It was the smallest increase since Tuesday.Deaths related to Covid-19 rose by 1,046 nationwide, the fifth-consecutive day with more than 1,000, though almost 300 fewer than the previous day, according to the data.CureVac Won’t Sell Virus Vaccine at Cost, CFO Tells FT (7:17 a.m. NY)CureVac NV won’t sell its coronavirus vaccine candidate at cost and instead plans to demand an “ethical” margin, the German company’s finance chief told the Financial Times.While the company still expects to sell the vaccine from mid-2021, things could move faster, Chief Executive Officer Franz-Werner Haas told the Boerse Online financial news site in an interview.“We are not ruling out accelerated approval, but it can only be achieved in close cooperation with authorities,” Haas was cited as saying.Nestle’s Swiss Sites Add Temperature Checks (6:40 a.m.
- 08/16/2020
|
U.S. Cases Slow as Deaths Pass 1,000 for Fifth Day: Virus Update
- (Bloomberg) -- The U.S. added 47,813 virus cases, a 0.9% rise that compares with a 1% increase over the previous week. Nationwide deaths exceeded 1,000 for the fifth consecutive day. A measure of intensive-care hospitalizations in California rose to the highest in seven weeks.Italy told nightclubs to close, matching a similar directive by Spain on Friday. France’s public health agency warned that all of the country’s Covid-19 indicators are trending upward.Russia agreed in principle with Saudi Arabia and the United Arab Emirates to conduct clinical trials of its coronavirus vaccine, the head of its sovereign wealth fund said. China and Russia may also work together on a vaccine, a Chinese virus expert said.Key Developments:Global Tracker: Global cases approach 21.5 million; deaths pass 771,500How $50,000-a-year private schools plan for Covid: NYC ReopensFirst into the virus slump, China is proving the fastest outRussia’s new Sputnik launch raises risks in dash for Covid shotsHow to inject excitement into a Covid-era party conventionRubber-glove boom spurred by pandemic creates billionaireSubscribe to a daily update on the virus from Bloomberg’s Prognosis team here. Click CVID on the terminal for global data on coronavirus cases and deaths.California ICU Trend Reaches Seven-Week High (2:05 p.m. NY)California added 7,873 new cases -- compared with the 14-day average of 8,029 -- bringing the total to 621,562. Deaths rose by 77 to 11,224.While the number of hospital patients fell to the lowest level since the end of June, the percentage of those in ICU increased to 31.8% based on a five-day average, the highest since late June, according to data on the state’s health department’s website. France Headed for Masks in Offices (1:48 p.m. NY)France reported 3,015 coronavirus cases in 24 hours, marking the second straight day with more than 3,000 new infections. One additional death was reported.“The situation is worrying: All indicators continue to increase and the transmission of the virus is on the rise,” the French public health agency said in a statement.French Labor Minister Elisabeth Borne will propose Tuesday that masks be required in businesses by September in places where people work together in an enclosed space, she said in an interview with Journal du Dimanche.She cited meeting rooms and common areas as places where masks would be required, and said she will discuss with the Health Ministry whether they’ll be needed in open-plan offices.Italy Closes Nightclubs, Widens Mask Orders (1:30 p.m. NY)The Italian government ordered nightclubs to close and broadened rules on wearing protective masks after talks Sunday with regional leaders.Dances in nightclubs, indoors and in the open will be suspended, Health Minister Roberto Speranza said in a Facebook post. Wearing masks will be compulsory from 6 p.m. to 6 a.m. in public spaces, including squares and streets where crowds can gather. Spain closed nightclubs on Friday.“We cannot nullify the sacrifices made in the past months,” Speranza wrote. Italy already requires people to wear face coverings on public transport and in shops among other indoor locations.Italy reported 479 new coronavirus cases Sunday after 629 a day earlier, which was the most since late May. The trend has been driven in part by Italians returning from vacations abroad.Ireland Warned on Possible New Curbs (1:07 p.m. NY)Irish Chief Medical Officer Ronan Glynn said authorities “will make any necessary recommendations” to the government to ensure a safe reopening of health-care services and schools.While the country’s phased reopening has allowed people to socialize again, “some are doing this recklessly,” Glynn said in a statement. Ireland reported 66 new Covid-19 cases on Sunday, compared with 200 a day earlier.Arizona Cases, Deaths Fall (11:40 a.m. NY)Arizona reported 883 cases, fewer than the previous day and in line with the average 0.5% daily increase from the week before. Total cases are 193,537. Reported deaths fell to 14, from 69 the day before, for a total of 4,506.Florida Cases, Deaths Slow (11 a.m. NY)Florida reported 573,416 cases, up 0.7% from a day earlier, compared with an average increase of 1.1% in the previous seven days. Deaths among Florida residents reached 9,452, an increase of 107, according to the state health department report, which includes data through Saturday. The state has reported four days in the last week with more than 200 deaths.New York Reports Fewer Cases (10:15 a.m. NY)New York reported 607 cases, a 0.1% rise compared with an average 0.2% increase from the previous seven days. Another six deaths were recorded, Governor Andrew Cuomo said in a tweet. Hospitalizations remained steady, and positive-test results stayed under 1%, he said.N.J. Governor Backs Biden Mask Plan (10 a.m. NY)New Jersey Governor Phil Murphy said on Sunday he supports Joe Biden’s suggestion that each state should require its people to wear face masks to curb the spread of the deadly coronavirus that continues to ravage the U.S.“The science and the data and the facts are unequivocal,” Murphy, who is also a co-chair for the Democratic National Committee’s presidential convention, said in an interview on Fox News Sunday with Chris Wallace. “I think we could accelerate dramatically driving this virus into the ground. It’s been a big weapon for us in New Jersey, but as a nation we’re only as strong as our weakest link. To have a national strategy I think would be a game changer.”Last month Murphy signed an executive order requiring people to wear face coverings when they are outside in public spaces and can’t socially distance.U.K. Cases Pass 1,000 Again (9:55 a.m. NY)U.K. cases increased by more than 1,000 for the sixth consecutive day and five more people died of Covid-19, according to figures from the Department of Health and Social Care.The latest daily figure for deaths, which includes all those who tested positive for coronavirus in the U.K. and then died within 28 days of that test, rose from three reported Saturday, according to the department. The number of new cases was up from 1,012 Saturday.Vietnam Confirms Coronavirus Death (8:06 a.m. NY)Vietnam’s health ministry confirmed one death from the coronavirus, and reported nine new local cases, three of them imported. That brings the total number of infections to 962.U.S. Rise in Cases Below 7-Day Average (8 a.m. NY)U.S. cases increased by 47,813, a 0.9% rise on the day. That’s lower than the 1% increase over the previous week, according to data compiled by Johns Hopkins University and Bloomberg. It was the smallest increase since Tuesday.Deaths related to Covid-19 rose by 1,046 nationwide, the fifth-consecutive day with more than 1,000, though almost 300 fewer than the previous day, according to the data.CureVac Won’t Sell Virus Vaccine at Cost, CFO Tells FT (7:17 a.m. NY)CureVac NV won’t sell its coronavirus vaccine candidate at cost and instead plans to demand an “ethical” margin, the German company’s finance chief told the Financial Times.While the company still expects to sell the vaccine from mid-2021, things could move faster, Chief Executive Officer Franz-Werner Haas told the Boerse Online financial news site in an interview.“We are not ruling out accelerated approval, but it can only be achieved in close cooperation with authorities,” Haas was cited as saying.Nestle Adds Temperature Checks at Swiss Sites (6:40 a.m. NY)Nestle SA has introduced temperature controls at the entrances of all its Swiss locations, including at headquarters and in Nespresso capsule production sites, SonntagsBlick reported. In total more than 10,000 employees are affected by the measures.Netherlands Tightens Travel Guidelines (6 a.m. NY)The Netherlands raised its travel advisory level to orange for three Spanish regions, including Madrid and the Balearic Islands, as well as for Paris and Brussels.The advisory, which discourages nonessential travel and requires self quarantine upon return to the Netherlands, was also raised for the Bouches-du-Rhone region in southern France, and three provinces in central and southern Spain.The Netherlands had earlier issued its orange travel advisory for the Belgian province of Antwerp and six provinces in Spain’s northeast, including those surrounding Barcelona and Lerida, which was at the center of a late-July outbreak.Philippine Recoveries Top 40,000 (4:50 a.m. NY)The Philippines reported 40,397 recoveries on Sunday after another automatic reclassification of mild and asymptomatic cases that have lapsed after 14 days.The “time-based” adjustment brings the total to 112,586 and means almost 70% of confirmed cases have recovered, Health Undersecretary Maria Rosario Vergeire said. New Covid-19 cases stood at 3,420, taking the tally to 161,253, the highest in Southeast Asia.China, Russia Plan Joint Tests: Chinese Scientist (4:35 a.m. NY)Zhong Nanshan, a top virus expert in China, said at a meeting on Sunday that China and Russia have plans to jointly conduct vaccine clinical trials, without giving further details. The meeting, held in China’s Guangdong province, is about virus cooperation between the two countries and attended by virus experts from both sides, according to local reports.Russian billionaire Vladimir Potanin’s drugmaker Petrovax is starting a phase III trial in Russia of Chinese company CanSino Biologics Inc.’s Ad5-nCoV vaccine candidate, it said on its website Saturday. Petrovax plans to produce the vaccine at its facilities in the Moscow Region once it’s registered in Russia.U.K. Putting Jobs in Danger, Think Tank Says (4:23 a.m. NY)U.K. Chancellor of the Exchequer Rishi Sunak is endangering 2 million viable jobs by ending his coronavirus jobs support program too early, the Institute for Public Policy Research said.
- 08/16/2020
|
U.S. IPO Weekly Recap: Coronavirus Vaccine Developer CureVac Pops 249% In A 4-IPO Week
- Four IPOs and six SPACs entered the public markets this past week led by CureVac, which posted the largest first-day pop for a US IPO since 2005.
- 08/15/2020
|
Covid Vaccine Contender CureVac More Than Triples in Debut
- (Bloomberg) -- CureVac BV soared 249% in its trading debut after raising $213 million in a U.S. initial public offering that boosted its profile in the race for a coronavirus vaccine.It was the best first-day performance by a wide margin among about 200 new listings on U.S. exchanges this year, according to data compiled by Bloomberg.“It is definitely a race,” CureVac Chief Executive Officer Franz-Werner Haas said in a Bloomberg TV interview. “It is a race not that much against the competition of other vaccine producers out there but a race against the virus. It is a race against time.”The company’s shares closed at $55.90 in New York trading Friday, giving the company a market value of $9.86 billion. CureVac sold 13.33 million shares Thursday for $16 each after marketing them for $14 to $16.CureVac, based in Tubingen, Germany, is also raising 100 million euros ($118 million) in a private placement concurrent with the IPO, according to CureVac’s filings with the U.S. Securities and Exchange Commission.Government StakeThe German government agreed in June to acquire 23% of the company for 300 million euros via development bank Kreditanstalt fuer Wiederaufbau, known as KfW.The offering was led by Bank of America Corp., Jefferies Financial Group Inc. and Credit Suisse Group AG. Shares of the company, which is being incorporated in the Netherlands and renamed CureVac NV in conjunction with the IPO, are trading on the Nasdaq Global Market under the symbol CVAC.CureVac, founded in 2000, said in June that it received regulatory approval to begin Phase 1 clinical trials of its Covid-19 vaccine candidate. It said in its filing that it expects the results of those trials in the fourth quarter.Transatlantic PrizeAs the coronavirus pandemic took hold, CureVac became the prize in a transatlantic competition to secure access to a potential vaccine after reports that the U.S. was angling to buy the company or its technology. In March, CureVac denied speculation that the U.S. government tried to buy the business or its technology.CureVac’s research is focused on messenger RNA, in which the vaccine teaches the body’s cells to identify and attack the virus. Some other companies trying to develop coronavirus vaccines, including Moderna Inc., based in Cambridge, Massachusetts, and German rival BioNTech SE, are already public.Moderna shares rose 2% on Friday, while BioNTech’s American depositary receipts fell 3.3%. The now second-best first-day performance for U.S. IPO is BigCommerce Holdings Inc., which closed up 201% in its debut.(Updates with CEO’s comments in third paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- 08/14/2020
|
COVID-19 vaccine maker CureVac pops 200% in debut
- Yahoo Finance's Anjalee Khemlani and Zack Guzman discuss COVID-19 vaccine maker Curevac's public debut and the UK Government signing vaccine deals with J&J and Novavax.
- 08/14/2020
|
CureVac's stock debuts at nearly triple the IPO price
- Shares of CureVac BV blasted off in their public debut Friday, as they opened at nearly triple the $16 initial public offering price. The Germany-based clinical stage biotechnology company raised $213.3 million in the IPO, which was priced at the top of the expected range of $14 to $16 a share, and valued the company at about $2.82 billion. The stock's first trade was at $44 at 12:17 p.m. Eastern for 1.2 million shares. The stock has pared some gains since, to trade up 141%. BofA Securities, Jefferies, Credit Suisse were joint bookrunners on the deal, with Berenber and Kempen & Co. acting as co-managers. The company had recorded a net loss of EUR23.9 million ($28.2 million) on revenue of EUR3.12 million for the three months ended March 31, after a loss of EUR21.3 million on revenue of EUR3.16 million in the same period a year ago. The company went public at a time that the Renaissance IPO ETF has rallied 29.9% over the past three months while the S&P 500 has advanced 18.3%.
- 08/14/2020
|
CureVac raises $213.3 million in IPO after pricing at $16 a share, high end of proposed range
- CureVac BV, a clinical-stage biotech headquartered in Germany, priced its initial public offering on Friday at $16 a share, the high end of its proposed range. The company sold 13.3 million shares to raise $213.3 million. The stock will start trading on Nasdaq later Friday under the ticker "CVAC." BofA Securities, Jefferies, Credit Suisse after joint bookrunners on the deal, with Berenber and Kempen & Co. acting as co-managers. Proceeds will be used to fund clinical research, R&D, to expand manufacturing facilities and for general corporate purposes. "We are a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people," the company says in its prospectus. "Our vision is to revolutionize medicine and open new avenues for developing therapies by enabling the body to make its own drugs."
- 08/14/2020
|
Vaccine Contender CureVac Raises $213 Million in IPO
- (Bloomberg) -- CureVac BV, a competitor in the race for a coronavirus vaccine, priced its U.S. initial public offering at the top of a marketed range to raise $213 million.The company sold 13.33 million shares for $16 each after marketing them for $14 to $16, according to a statement Friday. The company is also raising 100 million euros ($118 million) in a private placement concurrent with the IPO, according to CureVac’s filings with the U.S. Securities and Exchange Commission.CureVac, based in Tubingen, Germany, is valued in the listing at about $2.8 billion based on the outstanding shares listed in its filings. The company’s valuation could change depending on whether regulators approve a vaccine.The German government agreed in June to acquire 23% of the company for 300 million euros via development bank Kreditanstalt fuer Wiederaufbau, known as KfW.The offering is being led by Bank of America Corp., Jefferies Financial Group Inc. and Credit Suisse Group AG. Shares of the company, which being incorporated in the Netherlands and renamed CureVac NV in conjunction with the IPO, are expected to begin trading Friday on the Nasdaq Global Market under the symbol CVAC.CureVac, founded in 2000, said in June that it received regulatory approval to begin Phase 1 clinical trials of its Covid-19 vaccine candidate. It said in its filing that it expects the results of those trials in the fourth quarter.As the coronavirus pandemic took hold, CureVac became the prize in a transatlantic competition to secure access to a potential vaccine after reports that the U.S. was angling to buy the company or its technology. In March, CureVac denied speculation that the U.S. government tried to buy the business or its technology.CureVac’s research is focused on messenger RNA, in which the vaccine teaches the body’s cells to identify and attack the virus. Some other companies trying to develop coronavirus vaccines, including Moderna Inc., based in Cambridge, Massachusetts, and German rival BioNTech SE, are already public.(Updates with statement in second paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- 08/14/2020
|
